Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

191
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
191
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

171
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
171
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

229
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
229
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

225
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
225
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

242
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
242
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

401
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
401

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Ten Years of Hydroxyurea for Ugandan Children with Sickle Cell Anemia.

The New England journal of medicine·2026
Same author

Persistent Splenomegaly Is Associated with Morbidity in Tanzanian Children with Sickle Cell Anemia: Secondary Analysis of the SPHERE Trial.

Acta haematologica·2026
Same author

Growth and puberty in African children with sickle cell anemia treated with hydroxyurea.

Blood advances·2026
Same author

Creative and Adaptive Solutions for Early Diagnosis of Sickle Cell Disease in Sub-Saharan Africa.

American journal of hematology·2026
Same author

Advancing Sickle Cell Disease Treatment in Sub-Saharan Africa: Challenges and Opportunities for Disease Modifying Therapies.

American journal of hematology·2026
Same author

Sickle Cell Disease in Sub-Saharan Africa: Progress and Potential.

American journal of hematology·2026
Same journal

Neurocognitive functioning of patients with sickle cell disease in low- and middle-income countries.

Blood global hematology·2026
Same journal

Hodgkin lymphoma treatment patterns and outcome disparities in low- and middle-income countries.

Blood global hematology·2026
Same journal

Immunogenomic profiles of HIV-associated classic Hodgkin lymphoma from Malawi.

Blood global hematology·2026
Same journal

Clinical integration of red cell genotyping in children with β-thalassemia major: a prospective observational study.

Blood global hematology·2026
Same journal

Urinary carbonic anhydrase 1 excretion is a marker of hemolysis-triggering conditions suitable for point-of-care testing.

Blood global hematology·2026
Same journal

Asian-type DEL among D-negative patients and donors in Malaysia can ease the demand for D-negative red cells and RhIG.

Blood global hematology·2026
関連記事をすべて見る

関連する実験動画

Updated: Jan 8, 2026

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.9K

鎌状赤血球症小児における脳卒中リスク低減のためのヒドロキシウレア：系統的レビューとメタアナリシス

Emmanuela E Ambrose1, Paul Alikado Sabuni2, Don P Jason Iii3

  • 1Department of Pediatrics and Child Health, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.

Blood global hematology
|December 24, 2025
PubMed
まとめ
この要約は機械生成です。

ヒドロキシウレアは、異常な血流速度を低下させることにより、鎌状赤血球症（SCA）の小児における脳卒中リスクを効果的に低減する。この治療法は、特に資源の限られた地域において、輸血に代わる実行可能な選択肢である。

キーワード:
鎌状赤血球症ヒドロキシウレア脳卒中予防経頭蓋ドップラー小児血流速度

さらに関連する動画

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.2K
Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

16.5K

関連する実験動画

Last Updated: Jan 8, 2026

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.9K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.2K
Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

16.5K

科学分野:

  • 小児血液学
  • 神経学
  • 薬理学

背景:

  • 鎌状赤血球症（SCA）は、小児における脳卒中の原因となる遺伝性疾患である。
  • 経頭蓋ドップラー（TCD）超音波検査は、SCA患者の脳卒中リスクを評価する。
  • 現在の脳卒中予防には輸血が含まれるが、資源の限られた環境では限界がある。

研究 の 目的:

  • SCA小児におけるTCD速度および脳卒中リスク低減におけるヒドロキシウレアの有効性を系統的にレビューすること。
  • TCD速度に対するヒドロキシウレアの影響のサイズと期間を明らかにすること。

主な方法:

  • 5つの主要な医学データベースを横断して、前向き臨床試験の系統的レビューを実施した。
  • SCAの小児を対象とし、TCDスクリーニングを使用し、ヒドロキシウレア療法中の連続TCD速度および脳卒中発生率データを収集した試験を含めた。
  • 592人の参加者が関与した13件の試験からのデータを分析した。

主要な成果:

  • ヒドロキシウレアは、0.5年から2.6年の期間にわたり、平均TCD速度を-30 cm/s有意に低下させ、ほとんどの小児で正常化した。
  • 脳卒中発生率は低く（100人年あたり0.52-1.92件）、持続的に高いTCD値（>200 cm/s）を有する者のみで発生した。
  • ヒドロキシウレアは、TCD速度および関連する脳卒中リスクを低減する上で有効性を示した。

結論:

  • ヒドロキシウレアは、TCD速度を低減することにより、小児SCAにおける脳卒中リスクを軽減するための効果的な戦略である。
  • 特に資源の限られたヘルスケア環境において、血液輸血に代わる実行可能な選択肢となる。
  • 投与量の最適化、長期的な安全性の評価、および多様な集団における包括的な利益の評価のため、さらなる研究が必要である。